

Population Pharmacokinetics of Liposomal Irinotecan in Exposureâ€“Safety Analyses in Patients With Metastati

CPT: Pharmacometrics and Systems Pharmacology

,

DOI: 10.1002/psp4.12725

Citation Report

| # | ARTICLE | IF | CITATIONS |
|---|--|-----|-----------|
| 1 | Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer and Exposureâ€“Safety Analyses in Patients With Metastatic Pancreatic Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2021, , . | 1.3 | 5 |
| 2 | Recent developments of nanomedicine delivery systems for the treatment of pancreatic cancer. Journal of Drug Delivery Science and Technology, 2023, 79, 104042. | 1.4 | 1 |
| 3 | The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. ESMO Open, 2023, 8, 100746. | 2.0 | 2 |
| 4 | Population pharmacokinetic analysis of TQ-B3203 following intravenous administration of TQ-B3203 liposome injection in Chinese patients with advanced solid tumors. Frontiers in Pharmacology, 0, 14, . | 1.6 | 0 |